POSTER SESSION 2

Monday June 13, 2016: 12:45-14:15
Exhibition Space (30 Euston Square)

PS2

PS2-1

THE DETERMINANTS OF CHANGE IN THE COST-EFFECTIVENESS THRESHOLD
Mike Paulden, MA., MSc., University of Alberta, Edmonton, AB, Canada, Christopher McCabe, PhD, Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada and James O'Mahony, PhD, Trinity College Dublin, Dublin, Ireland
PS2-2

THE PRICE OF A CURE? ESTABLISHING THE VALUE BASED PRICE OF CAR-T CELL THERAPY FOR ACUTE LYMPHOBLASTIC LEUKAEMIA
Sebastian Hinde, MSc, Centre for Health Economics,, Heslington, United Kingdom, Stephen Palmer, PhD, University of York, York, United Kingdom and Robert Hettle, PAREXEL Intermational, London, United Kingdom
PS2-3

ESTIMATING THE COST-EFFECTIVENESS OF USING CIRCULATING TUMOR CELL DETECTION TO GUIDE SYSTEMIC THERAPY IN STAGE IA PRIMARY BREAST CANCER
Sofie Berghuis, MSc, Hendrik Koffijberg, PhD and Maarten J. IJzerman, PhD, University of Twente, Enschede, Netherlands
PS2-4

TEN WAYS TO ENHANCE THE ESTIMATION, REPORTING AND INTERPRETATION OF THE COST-EFFECTIVENESS OF CANCER SCREENING INTERVENTIONS
James O'Mahony, PhD, Trinity College Dublin, Dublin, Ireland
PS2-5

CONTINGENCY MANAGEMENT IMPROVES COMPLETION OF HEPATITIS B VACCINATION IN THOSE ON TREATMENT FOR OPIATE DEPENDENCE: AN ECONOMIC EVALUATION
Rachid Rafia, MSc1, Pete Dodd, MSc, PhD1, Alan Brennan, MSc, PhD1, Petra Meier, MSc, PhD2, Vivian Hope, PhD MMedSc BSc (Hons)3, Fortune Ncube, BMedSci, BM/S, DRCOG, MSc PHM, FFPHM,3, Sarah Byford, MSc, PhD4, Nicola Metrebian, MSc, PhD5, Jennifer Hellier, MSc5, Tim Weaver, MSc, PhD6 and John Strang, MSc, PhD5, (1)Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, United Kingdom, (2)Section of Public Health, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, United Kingdom, (3)Centre for Infectious Disease Surveillance and Control, Public Health England, London, United Kingdom, (4)Centre for the Economics of Mental & Physical Health (CEMPH), Institute of Psychiatry, KingÂ’s College London, London, United Kingdom, (5)Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, London, United Kingdom, (6)Department of Mental Health, Social Work and Integrative Medicine, London, United Kingdom
PS2-6

DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP
Gaby Sroczynski, MPH, Dr.PH1, Annette Conrads-Frank, PhD1, Felicitas Kuehne, MSc1, Nikolai Mühlberger, Assist.-Prof., DVM, MPH1, Gregoire Jeanblanc, MD2, Aurore Duguet, PharmD2, Derek Misurski, PhD3, Jennifer Samp, PHARMD, MS3, Isabelle Durand-Zaleski, Prof., MD, PhD4 and Uwe Siebert, MD, MPH, MSc, ScD5, (1)Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, (2)AbbVie Inc., Rungis, France, (3)AbbVie Inc., North Chicago, IL, (4)URC Eco Ile de France Hopital de l'Hotel Dieu, Paris, France, (5)UMIT, Dept. of Public Health, Health Services Research and Health Technology, Hall in Tirol, Austria
PS2-7

THE DEVELOPMENT OF EXPERTISE IN NON-MEDICAL PERSONNEL INTERPRETING DIAGNOSTIC MAMMOGRAMS
Anne-Marie Culpan, PhD. MRes, MHSc, PGCHEP, DMU, DCRR and Paul Marshall, PhD, BSc, University of Leeds, Leeds, United Kingdom
PS2-8

ONCOLOGIST AND PATIENT QUESTIONS DURING CONSULTATIONS ABOUT ADJUVANT CANCER TREATMENT: A SHARED DECISION-MAKING PERSPECTIVE
Arwen Pieterse, PhD1, Marleen Kunneman, PhD2, Ellen Engelhardt, Msc1, Niels Brouwer1, Judith Kroep, PhD1, Corrie Marijnen, PhD1, Anne M. Stiggelbout, PhD1 and Ellen Smets, PhD2, (1)Leiden University Medical Center, Leiden, Netherlands, (2)Amsterdam Medical Center/University of Amsterdam, Amsterdam, Netherlands
PS2-9

DISCLOSING THE UNCERTAINTY OF PROGNOSTIC ESTIMATES IN BREAST CANCER: CURRENT PRACTICES AND PATIENTS' AWARENESS OF UNCERTAINTY
Ellen G. Engelhardt, MSc.1, Ellen MA Smets, PhD2, Paul K. J. Han, MD, MA, MPH3, Judith R. Kroep, MD PhD1, Johanneke Portielje, MD, PhD4, J. (Hanneke) CJM de Haes, PhD2, Arwen H. Pieterse, PhD1 and Anne M. Stiggelbout, PhD1, (1)Leiden University Medical Center, Leiden, Netherlands, (2)Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, (3)Maine Medical Center Research Institute, Portland, ME, (4)Haga Ziekenuis, The Hague, Netherlands
PS2-10

EFFECTIVENESS OF DIETARY INTERVENTIONS IN CHRONIC KIDNEY DISEASE (CKD): A SYSTEMATIC REVIEW
Helen Scott1, Andrew Mooney1 and Hilary Bekker2, (1)Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, (2)University of Leeds, Leeds, United Kingdom
PS2-11

THE IMPORTANCE OF A GOOD RELATIONSHIP WITH THE CLINICIAN: A CRITICAL FACTOR FOR COLLABORATIVE GOAL SETTING DISCUSSIONS ACCORDING TO PATIENTS
Heather Morris, PhD, University of Florida, Gainesville, FL
PS2-12

CHALLENGES OF COMMUNICATING PROGNOSTIC ESTIMATES FOR DECISIONS ABOUT LIFE SUPPORT – THE EVOLUTION OF A DECISION AID TO FACILITATE SHARED DECISION MAKING ABOUT MECHANICAL VENTILATION
Negin Hajizadeh, MD, MPH1, Melissa Basile, PhD2 and Andrzej Kozikowski, PhD2, (1)Hofstra Northwell LIJ School of Medicine, Manhasset, NY, (2)North Shore LIJ Health System, Manhasset, NY
PS2-13

CONFIDENCE IN DECISION MAKING OF PARAMEDIC CREW LEADERS: ITS LEVEL, ROOTS AND POSSIBLE CONSEQUENCES
Jitka Gurnakova, PhD., Institute of Experimental Psychology, Bratislava, Slovakia
PS2-14

SYNTHESIS OF THREE DATA SOURCES TO DETERMINE INDEPENDENT VARIABLES IN AN ONLINE FACTORIAL SURVEY OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR DEACTIVATION DECISIONS
Loreena Hill, PhD1, Brian Taylor, PhD2, Sonja McIlfatrick, PhD2 and Donna Fitzsimons, PhD2, (1)Belfast Health and Social Care Trust, Belfast, United Kingdom, (2)Ulster University, Northern Ireland, United Kingdom
PS2-15

DIAGNOSTIC ACCURACY OF LEVEL IV PORTABLE SLEEP TESTS VERSUS POLYSOMNOGRAPHY FOR SLEEP-DISORDERED BREATHING: A SYSTEMATIC REVIEW AND META-ANALYSIS
Lusine Abrahamyan, MD, MPH, PhD1, Yeva Sahakyan, MD, MPH2, Suzanne Chung2, Petros Pechlivanoglou, MSc, PhD2, Steven M. Carcone, MSc2, Valeria E. Rac, MD, PhD1 and Murray Krahn, MD, MSc, FRCPC1, (1)Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, (2)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada
PS2-16

DOMINANT ASPIRIN THERAPY STRATEGY ELIMINATES ROLE FOR IMAGING SCREENING/WARFARIN THERAPY FOR STROKE PREVENTION IN MODEL OF ASYMPTOMATIC BLUNT NECK TRAUMA
Rajeev Nowrangi, MD MPH1, Steven Munson, MD2, Udo E. Oyoyo, MPH3 and J. Paul Jacobson, MD MPH1, (1)Loma Linda University Medical Center, Loma Linda, CA, (2)John L. McClellan Memorial Veterans Hospital, Little Rock, AR, (3)Loma Linda University, Loma Linda, CA
PS2-17

THE USE OF SPECIALTY TRAINING TO RETAIN DOCTORS IN MALAWI: A DISCRETE CHOICE EXPERIMENT
Kate Mandeville1, Godwin Ulaya2, Mylene Lagarde1, Adamson Muula3, Titha Dzowela4 and Kara Hanson1, (1)London School of Hygiene and Tropical Medicine, London, United Kingdom, (2)Blantyre Health Research and Training Trust, Blantyre, Malawi, (3)College of Medicine-University of Malawi, Blantyre, Malawi, (4)Christian Health Association of Malawi, Lilongwe, Malawi
PS2-18

COMPOSITE EVALUATIONS OF TESTS: MULTIPLE PRIMARY STUDIES INTEGRATED WITH AN ECONOMIC MODEL. EXPERIENCE WITH TWO CASES
Christopher Hyde and Jaime Peters, Institute for Health Research, University of Exeter Medical School, Exeter, United Kingdom
PS2-19

IMPROVING DIAGNOSTIC DECISION MAKING FOR A RARE DISEASE: IDENTIFYING BARRIERS TO EARLY DIAGNOSIS OF SCHWANNOMATOSIS
Vanessa Merker, BS1, Jaishri Blakeley, MD2, A. Rani Elwy, PhD1, Martin Charns, DBA1, Mark Meterko, PhD1 and Scott Plotkin, MD, PhD3, (1)Boston University School of Public Health, Boston, MA, (2)Johns Hopkins Medical Institute, Baltimore, MD, (3)Massachusetts General Hospital, Boston, MA, MA
PS2-20

CLINICIAN-IDENTIFIED PRIORITIES FOR MEDICATION SAFETY IN PRIMARY CARE: A PRIORITIZE STUDY
Lorainne Tudor Car, Nikolaos Papachristou, Mona El-Khatib, Paul Aylin and Azeem Majeed, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom
PS2-21

THRESHOLD-BASED GUIDELINES THREATEN PREFERENCE-SENSITIVE DECISION MAKING IN PERSON-CENTRED CARE
Mette Kjer Kaltoft, PhD, Odense University Hospital - Svendborg, Svendborg, Denmark, Jesper Bo Nielsen, PhD, University of Southern Denmark, Odense, Denmark, Glenn Salkeld, PhD, University of Wollongong, Wollongong, Australia and Jack Dowie, PhD, LSHTM, London, United Kingdom
PS2-22

CLINICAL UTILITY OF PREDICTION MODELS FOR OVARIAN TUMOR DIAGNOSIS: A DECISION CURVE ANALYSIS
Laure Wynants1, Jan Verbakel2, Sabine Van Huffel1, Dirk Timmerman2 and Ben Van Calster2, (1)KU Leuven, Department of Electrical Engineering (ESAT), STADIUS Center for Dynamical Systems, Signal Processing and Data Analytics, Leuven, Belgium, (2)KU Leuven Department of Development and Regeneration, Leuven, Belgium
PS2-23

MISSES VS. FALSE ALARMS IN HIGH-STAKES DECISIONS: QUANTIFYING BENEFITS–HARMS RATIOS FOR POLICY ANALYSIS IN MEDICAL DECISION MAKING
Stefan Herzog, Dr., Max Planck Institute for Human Development, Berlin, Berlin, Germany
See more of: 16th Biennial European Conference
<< Previous Session | Next Session >>